Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, S. Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Article numbere334
JournalBlood cancer journal
Issue number8
StatePublished - Aug 14 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this